Scientists have demonstrated that glioblastoma (GBM) tumour stem cells became less able to proliferate and invade tissues when the production of the prion protein was blocked, highlighting a potential new therapeutic target. 

GBM, which accounts for nearly half (49%) of all brain tumours, has an extremely low survival rate, with most patients living only about 12 months after diagnosis. 

After treatment, the glioblastoma stem cells remain dormant in the brain tissue and can become active again. 

A group led by Professor Marilene Hohmuth Lopes, of the Laboratory of Neurobiology and Stem Cells in the Department of Cell and Developmental Biology at the Biomedical Sciences Institute of the University of São Paulo (ICB-USP) in Brazil, investigated the mechanism of action of the tumour cells that remain in the brain tissue after treatment. 

In a study supported by FAPESP and published in the journal BMC Cancer, the team discovered that the prion protein plays a key role. 

Lopes explained: “When we observed in patient samples that it was elevated in very aggressive tumours, we decided to better understand its relationship with glioblastoma and its influence on the tumour stem cells responsible for cancer recurrence.” 

The group used CRISPR-Cas9 to edit the genome of glioblastoma stem cells and block the production of the prion protein in these cells. 

“It’s unlikely that a single protein alone is responsible for the development of the disease. We believe that it acts in different signalling pathways, which is why we’re continuing to investigate other mechanisms and possible partners for the protein,” added Lopes. 

“We’re in the process of understanding mechanisms, of understanding how this protein regulates other important genes in cell and tumour biology, and how it could become a potential therapeutic target in the future.” 

Diana Spencer, Senior Digital Content Editor, DDW